Key result
SEA0400 is a highly potent and selective inhibitor of the Na+-Ca2+ exchanger that attenuates ischemia-reperfusion injury in preclinical models of the brain, heart, and kidney.
Population
Preclinical models including cultured rat neurons, astrocytes, microglia, canine cardiac sarcolemmal…
Design
Review
Authors
Loading...
Supports NCX inhibition in preclinical ischemia-reperfusion models; leaves open clinical translation.
SEA0400 is a highly selective and potent inhibitor of the Na+-Ca2+ exchanger that shows promise in preclinical models for reducing ischemia-reperfusion injury and edema.
Matsuda et al. (2005) conducted a review in Ischemia-reperfusion injury, edema, and hypertension (preclinical models). SEA0400 was evaluated. SEA0400 is a highly potent and selective inhibitor of the Na+-Ca2+ exchanger that attenuates ischemia-reperfusion injury in preclinical models of the brain, heart, and kidney.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: